|
|
Crucial Conversations in Oncology Nursing: Management Considerations for the AML Patient
The landscape of AML treatment is evolving and newer targeted agents may improve outcomes for selected subgroups of patients. Oncology nursing professionals provide disease and treatment information, manage adverse effects, and offer emotional support. Knowledge of the key management issues for patients with AML is critical in fulfilling this role. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and po... |
|
|
12th International Congress on Myeloproliferative Neoplasms
Since its inception 18 years ago, the International Congress on Myeloproliferative Neoplasms has provided a forum for the interaction of practicing hematologists, oncologists, translational scientists, and other healthcare professionals with experts from both the US and Europe in the myeloproliferative neoplasms, including chronic myeloid leukemia, the hyper-eosinophilic syndromes and mastocytosis. This year’s CME-accredited program will feature the latest information on the pathophysiology ... |
|
|
TKI Therapy in CML: Emerging Treatments, Ensuring Safety
This Virtual Practice summarizes advances in tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) in the context of disease- and patient-specific characteristics; reviews the most effective methods for monitoring early response and long-term therapeutic outcomes; assesses the milestones and mutational analyses to identify when a change in TKI therapy is needed; compares toxicity profiles of the currently available TKI agents; and examines how toxicity could interact with... |
|
|
Clinical Updates in Chronic Myeloid Leukemia: New Understandings in Disease Diagnosis, Monitoring and Personalized Therapeutic Regimens Utilizing Tyrosine Kinase Inhibitors
Advance your understanding on how to better diagnose, treat, and monitor CML. Expert faculty from MD Anderson recently gave a series of lectures across the country on the latest research and treatment regimen recommendations in CML. Highlighting key takeaways from this meeting series, faculty review the role of ABL tyrosine kinase inhibitor (TKI) agents in advancing treatment and delivering up-to-date care as well as discuss safety and tolerability of various approved TKIs in CML. They examine... |
|